Search Results for “Novo Nordisk ” – Page 13 – media

Wegovy could prevent up to 1.5 million heart attacks, strokes over 10 years, study says

Novo Nordisk’s blockbuster weight loss injection Wegovy could prevent up to 1.5 million heart attacks, strokes and other cardiovascular events in the U.S. over 10 years, according to a study released this week. Researchers from the University of California, Irvine, also found that Wegovy could result in 43 million fewer Americans with obesity over a decade. Notably, the study was partly funded by Novo Nordisk. The study results complement the initial data the Danish company released last week from a large clinical trial, which found that Wegovy slashed the risk of serious heart problems and heart-related death by 20%. Novo Nordisk’s trial studied overweight or obese patients with established cardiovascular disease, while UC Irvine’s study examined similar patients, albeit without the disease. Together, the results suggest that Wegovy and, likely, similar obesity drugs have significant health benefits beyond shedding unwanted pounds. Physicians and Wall Street analysts hope that could eventually ...
- Source: drugdu
- 200
- August 18, 2023
Wegovy shown to reduce risk of heart attack, stroke in major cardiovascular trial

By Meg Tirrell, CNN The weight loss drug Wegovy was shown to reduce the risk of heart attack, stroke or heart-related death by 20% in what’s being called a landmark clinical trial in people with cardiovascular disease, the first to show a weight loss drug alone can have such protective effects. Novo Nordisk studied Wegovy against placebo in addition to standard of care for prevention of major adverse cardiac events in 17,604 adults with heart disease and obesity or who were overweight, but who didn’t have diabetes. It called the five-year trial “Select.” The finding of a 20% reduction in heart risk is higher than many experts had anticipated. A similar trial for the type 2 diabetes drug Ozempic, which uses the same ingredient, semaglutide, previously showed it could reduce cardiovascular risk by 26% — but no trial had yet shown a risk reduction in people without diabetes. “Historically, trials ...
- Source: drugdu
- 129
- August 11, 2023
Eco-minded AstraZeneca doubles down on renewable energy push in Sweden

AstraZeneca is often at the forefront when it comes to sustainability efforts among pharma companies. Now, the British drugmaker is doubling down on its clean energy commitments in Sweden. AstraZeneca and Stratkraft—Europe’s largest renewable energy producer—have entered into an agreement on wind power deliveries that will increase the supply of renewable electricity in Sweden based on the commissioning of new wind farms, the companies said Wednesday. Under the deal, AZ will purchase 200 gigawatt-hours per year for 10 years, the partners explained. That amount corresponds to roughly 80% of the company’s total electricity needs at its research facility in Gothenburg and its manufacturing plant in Södertälje. The wind farms for this project will be located in Strömstad and Årjäng, in the same region as AZ’s research and manufacturing facilities. Across its Swedish operations, AstraZeneca is also working to cut back on its electricity consumption. One way it’s meeting this goal ...
- Source: drugdu
- 114
- August 11, 2023
Merck and Ginkgo Bioworks enter biologic manufacturing collaboration worth up to $490m

Merck & Co – known as MSD outside the US and Canada – and Ginkgo Bioworks have announced a new biologic manufacturing collaboration worth up to $490m. The partnership will utilise Ginkgo’s capabilities in cell engineering, ultra high-throughput multiplexed screening, protein characterisation and process optimisation to improve production efficiency and increase yields. In exchange, Ginkgo could receive up to $490m in upfront research fees, research milestone fees, option licence payments and commercial milestone payments. Jason Kelly, chief executive officer and co-founder of Ginkgo, said: “We’re thrilled to leverage our platform to improve the production of biologics in collaboration with Merck. “In particular, we will utilise some of our unique capabilities, such as automated protocols to do predictive ultra high-throughput multiplexed screening, product characterisation and process optimisation.” Also commenting on the collaboration, Dr Michael Kress, senior vice president, development sciences and clinical supply at Merck Research Laboratories, said: “At Merck we ...
- Source: drugdu
- 109
- August 10, 2023
UK Probes Weight Loss, Diabetes Drugs for Suicidal Ideation and Self-Harm Risk

The UK’s Medicines and Healthcare products Regulatory Agency said Wednesday that it is reviewing a class of drugs used for obesity and diabetes treatment after reports of self-injury and suicidal thoughts in patients. The probe by the MHRA comes shortly after the European Medicines Agency (EMA) expanded its own investigation into the GLP-1 receptor agonist class of drugs. This includes medications like Saxenda (liraglutide), Wegovy (semaglutide) and Ozempic (semaglutide) produced by Danish pharma company Novo Nordisk. According to reporting by Reuters, the MHRA also confirmed AstraZeneca’s Bydureon (exenatide), Sanofi’s lixisenatide, and Eli Lilly’s dulaglutide were also being included in the review. Novo Nordisk told Reuters that it had received a request from the MHRA about the investigation. “The review is ongoing and a response will be provided within the requested timelines,” Novo Nordisk said in a statement. The MHRA review kicked off July 12, though the agency could not specify when it would ...
- Source: drugdu
- 120
- July 28, 2023
Pfizer and Flagship Pioneering Sign Drug Discovery Partnership Worth up to $7bn

Pfizer has signed a deal with Flagship Pioneering worth up to $7bn to develop new drug candidates using the venture firm’s large portfolio of biopharma companies. Under the terms of the agreement, Pfizer and Flagship will each invest $50m upfront to develop a new pipeline of up to ten programmes for areas including internal medicine, oncology, infectious diseases, and immunology. The new partners outlined in a statement that the collaboration will focus on addressing unmet needs within Pfizer’s core therapeutic areas, including “broad patient populations and diseases with high potential to benefit from a diverse range of technology platforms and modalities”. Flagship’s drug discovery initiative, Pioneering Medicines, working in collaboration with Pfizer’s research and development leadership, will lead the exploration process. Paul Biondi, president, Pioneering Medicines, and executive partner, Flagship Pioneering, said: “This new partnership brings together the best of our organisations to maximise discovery and ...
- Source: drugdu
- 111
- July 24, 2023
Pfizer, Flagship Team Up in $100M R&D Pact — 10 New Drugs for Unmet Needs

Pfizer and Flagship Pioneering are partnering in a drug research alliance leveraging the capabilities of the more than 40 biotech startups in the venture capital firm’s portfolio. The new partners aim to develop drugs for unmet needs, including those in broad patient populations. Pharmaceutical companies frequently strike deals with smaller biotech companies as a way to build up their drug pipelines, and Pfizer is no exception. But in a twist to this strategy, the pharma giant is now turning to Flagship Pioneering, the venture capital firm whose highest profile creation might be the messenger RNA company Moderna. The alliance announced Tuesday calls for Flagship and Pfizer to each invest $50 million up front. The cash will go toward the R&D of 10 single-asset programs. Flagship does not create single-asset companies. The startups that spring from its labs are all formed around platform technologies, each with the capability of yielding ...
- Source: drugdu
- 130
- July 20, 2023
NVIDIA Invests $50m in AI-enabled Drug Discovery

NVIDIA has announced a $50m private investment in public equity in tech-focused Recursion Pharmaceuticals to create artificial intelligence (AI)-assisted drug discovery models, sending Recursion’s stock to skyrocket. This investment and partnership news was followed by a 116 % rise in Recursion’s stock price when markets opened on 12 July, compared to the previous day. The investment is accompanied by plans for collaboration to distribute these using NVIDIA cloud services and follows the strategic acquisition of Cyclica and Valence to enhance Recursion’s machine-learning and AI capabilities. This year, there has been an increased focus on using AI in drug discovery among other applications. Several companies have touted their reliance on AI, with Insilico Medicine’s AI-discovered drug for idiopathic pulmonary fibrosis starting its Phase II trial. GlobalData analysts have identified more than 250 unique active drugs using terms such as “AI” or “machine learning” in their drug description ...
- Source: drugdu
- 126
- July 17, 2023
EMA Concern Stirs over Suicide Risk with Weight Loss GLP-1RA Drugs

The European Medicines Agency (EMA) is reviewing data on the potential effects of high-profile glucagon-like peptide-1 receptor agonists (GLP-1RAs), including Novo Nordisk’s Ozempic (semaglutide), Saxenda (liraglutide) and Wegovy (semaglutide) in causing suicidal thoughts and thoughts of self-harm. The EMA has previously approved these drugs for weight loss and/or as treatments for type 2 diabetes. The EMA investigation comes after the Icelandic Medicines Agency flagged reports of suicidal thoughts and self-injury in patients taking Ozempic and Saxenda. Authorities are so far investigating 150 reports of possible cases of self-injury and suicidal thoughts. Led by the Pharmacovigilance Risk Assessment Committee (PRAC), the EMA evaluation aims to find if these symptoms are linked to the medicines themselves, are unrelated or caused by other underlying factors. The EMA reports that more than 20 million patients in the EU have so far used liraglutide and semaglutide. GLP-1RAs are a rapidly growing ...
- Source: drugdu
- 107
- July 14, 2023
Zealand Pharma submits NDA for hyperinsulinism drug dasiglucagon

Zealand Pharma has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for its treatment dasiglucagon for use in paediatric patients aged seven days or older with congenital hyperinsulinism (CHI). Based on an announcement released on 30 June, the application is based on clinical data from two Phase III studies and interim results from an ongoing long-term extension trial (NCT03941236). This includes results from a Phase III trial (NCT041724412), which tested dasiglucagon’s efficacy and safety in a hospital setting among 12 neonates and infants with CHI aged seven days to 12 months. In the first part of the trial, which took the form of a 48-hour crossover study, dasiglucagon reduced the need for glucose infusions by 55%. The application also features data from a second Phase III study (NCT03777176), which tested subcutaneous dasiglucagon infusions in 32 children with CHI aged three months to 12 years. ...
- Source: drugdu
- 115
- July 5, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.